Clinical Trials
18 trialsNCT05294900 2026-05-26
NEOS
Yonsei University
Phase 2 Completed
NCT05061550 2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2 Recruiting
NCT06102252 2026-05-22
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma
Sohag University
Phase NA Completed
NCT07365319 2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Recruiting
NCT02453282 2026-05-12
MYSTIC
AstraZeneca
Phase 3 Active not recruiting
NCT03609047 2026-05-12
Appalaches
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT02542293 2026-05-01
NEPTUNE
AstraZeneca
Phase 3 Active not recruiting
NCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
NCT03003962 2026-03-11
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
Phase 3 Active not recruiting
NCT07102940 2026-02-20
Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
George Washington University
Phase 2 Not yet recruiting
NCT07401654 2026-02-10
The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06430437 2026-01-21
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07171606 2025-12-18
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Recruiting
NCT06353906 2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05201547 2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3 Active not recruiting
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT03519971 2025-10-28
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT07107217 2025-08-17
Camella
Blokhin's Russian Cancer Research Center
Phase 2 Not yet recruiting